Literature DB >> 8130393

Processing of asparagine-linked oligosaccharides in insect cells. N-acetylglucosaminyltransferase I and II activities in cultured lepidopteran cells.

F Altmann1, G Kornfeld, T Dalik, E Staudacher, J Glössl.   

Abstract

The levels of beta 1,2-N-acetylglucosaminyltransferase (GlcNAc-T) I and II activities in cultured cells from Bombyx mori (Bm-N), Mamestra brassicae (IZD-Mb-0503) and Spodoptera frugiperda (Sf-9 and Sf-21) were investigated. Apart from initial experiments with Man alpha-3(Man alpha 1-6)-Man beta 1-O(CH2)8COOH3 and 3H-labelled UDP-GlcNAc as substrates, GlcNAc-T I activity was measured with a non-radioactive HPLC method using pyridylaminated Man3-GlcNAc2 and Man5GlcNAc2 as acceptor oligosaccharides. It was shown by reversed-phase HPLC, exoglycosidase digestion and methylation analysis that the product obtained with Man3GlcNAc2 contained a terminal GlcNAc residue linked beta 1,2 to the alpha 1,3 arm of the acceptor. Compared to the enzyme from the human hepatoma cell line HepG2, insect cell GlcNAc-T I exhibited a much higher preference for the Man5 substrate. The GlcNAc-T I from Mb-0503 cells had apparent Km and Vmax values for pyridylaminated Man3- and Man5GlcNAc2 of 2.15 and 0.21 mM, and of 3.4 and 11.4 nmol/h/mg of cell protein, respectively. When Man5GlcNAc2 was used as the acceptor substrate, the levels of GlcNAc-T I activity in the four insect cell lines ranged between 7.5 and 14.7 nmol/h/mg of cell protein, and thus were comparable to that of HepG2 cells. Evidence is presented for the dependence of lepidopteran fucosyltransferase on the presence of terminal N-acetylglucosamine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8130393     DOI: 10.1093/glycob/3.6.619

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  46 in total

1.  Improved glycosylation of a foreign protein by Tn-5B1-4 cells engineered to express mammalian glycosyltransferases.

Authors:  K Breitbach; D L Jarvis
Journal:  Biotechnol Bioeng       Date:  2001-08-05       Impact factor: 4.530

2.  Novel baculovirus expression vectors that provide sialylation of recombinant glycoproteins in lepidopteran insect cells.

Authors:  D L Jarvis; D Howe; J J Aumiller
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Insect cells encode a class II alpha-mannosidase with unique properties.

Authors:  Z Kawar; K Karaveg; K W Moremen; D L Jarvis
Journal:  J Biol Chem       Date:  2001-02-09       Impact factor: 5.157

Review 4.  Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production.

Authors:  Donald L Jarvis
Journal:  Virology       Date:  2003-05-25       Impact factor: 3.616

Review 5.  Lepidopteran cells, an alternative for the production of recombinant antibodies?

Authors:  Martine Cérutti; Josée Golay
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

6.  Post-translational modifications in insect cells.

Authors:  H D Klenk
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

Review 7.  Protein N-glycosylation in the baculovirus-insect cell system.

Authors:  Xianzong Shi; Donald L Jarvis
Journal:  Curr Drug Targets       Date:  2007-10       Impact factor: 3.465

8.  Kinetic comparison of peptide: N-glycosidases F and A reveals several differences in substrate specificity.

Authors:  F Altmann; S Schweiszer; C Weber
Journal:  Glycoconj J       Date:  1995-02       Impact factor: 2.916

9.  Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952.

Authors:  K D Greis; W Gibson; G W Hart
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  N-acetyl-beta-glucosaminidase accounts for differences in glycosylation of influenza virus hemagglutinin expressed in insect cells from a baculovirus vector.

Authors:  R Wagner; H Geyer; R Geyer; H D Klenk
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.